Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | MPC2 | O95563 | 2/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24051118 | 0.81 | PPARG (0.52) | PPARGCYP2C9MPC2CYP2C8SMN1; SMN2 | |
| SCHEMBL936483 | 0.81 | PPARG (0.72) | PPARGCYP2C9MPC2CYP2C8FFAR1 | |
| SCHEMBL25832955 | 0.79 | PPARG (0.49) | PPARGCYP2C9MPC2CYP2C8FFAR1 | |
| SCHEMBL8282070 | 0.77 | PPARG (0.47) | PPARGCYP2C9MPC2CYP2C8LMNA | |
| SCHEMBL21504819 | 0.75 | PPARG (0.50) | PPARGCYP2C9MPC2CYP2C8SMN1; SMN2 | |
| SCHEMBL19217857 | 0.74 | PPARG (0.49) | PPARGCYP2C9MPC2CYP2C8LMNA | |
| SCHEMBL29207071 | 0.72 | RAB9A (0.56) | LMNASMN1; SMN2RAB9AMAPTNPSR1 | |
| SCHEMBL18541489 | 0.68 | PPARG (0.73) | PPARGCYP2C9MPC2CYP2C8FFAR1 | |
| SCHEMBL12628141 | 0.68 | PPARG (0.73) | PPARGCYP2C9MPC2CYP2C8FFAR1 | |
| SCHEMBL936978 | 0.68 | PPARG (0.73) | PPARGCYP2C9MPC2CYP2C8FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361629-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361629-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | PPARD, FABP1, GOT2 | PPARG 4/4885CYP2C9 1337/4885MPC2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.